Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining beta-cell function and achievement of HbA1c target one year after initiation

摘要

Aims: The GLP-1 receptor agonist liraglutide improves impaired pancreatic beta-cell function, thereby exerting glucose-lowering effects. However, the association of remaining beta-cell function with long-term therapeutic efficacy of liraglutide remains largely unknown.